Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06170268 · ClinicalTrials.gov registry record
Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)
A clinical trial of Alzheimer Disease, sponsored by Alzheimer's Disease and Related Disorders Association.
- Recruiting
- Registry status
- 20,000
- Enrollment target
- 1
- Study location
NCT06170268: Recruiting study of Alzheimer Disease, sponsored by Alzheimer's Disease and Related Disorders Association.
NCT06170268 is a study of Alzheimer Disease that is actively recruiting participants, run by Alzheimer's Disease and Related Disorders Association. The registered enrollment target is 20,000 participants, above the 2,685-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (645% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06170268, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Alzheimer's Disease and Related Disorders Association.
- RECRUITING
- Registry status
- 20,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) will collect longitudinal clinical and safety data for enrolled patients being evaluated for or treated with novel FDA-approved Alzheimer's disease (AD) therapies. ALZ-NET is a longitudinal registry with an expandable platform, designed to grow with scientific and medical advancements. As new treatments are approved and implemented in care, ALZ-NET will track the long-term health outcomes associated with their use in a real-world setting. ALZ-NET is a resource for evidence gathering, information sharing and education across clinical and research communities, encouraging innovative research and supporting opportunities to improve clinical care delivery. All participating physicians and site staff will complete comprehensive training to ensure adherence of data requirements and registry timelines.
Primary Outcome
The primary measure of cognitive status will be the overall score of Montreal Cognitive Assessment (MoCA). MoCA is measured on a scale of 0 to 30 with higher scores indicating better cognitive function.
Conditions Studied
Interventions
- OTHER Routine Care Documentation
Study Locations (1)
Illinois
- Full List of Active Sites - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2022-10-20 |
| Est. Completion | 2032-12 |
What NCT06170268 shows while recruiting
NCT06170268 is an observational study that tracks outcomes without assigning an intervention. Its 20,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,685-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (645% higher).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Routine Care Documentation is the first listed.
NCT06170268 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06170268 about?
NCT06170268 is a clinical study titled "Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)". The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) will collect longitudinal clinical and safety data for enrolled patients being evaluated for or treated with novel FDA-approved Alzheimer's disease (AD) therapies. ALZ-NET is a longitudinal registry with an expandable platform, designed...
What is the current status of trial NCT06170268?
This trial is currently recruiting. The enrollment target is 20,000 participants. The study started on 2022-10-20. Estimated completion is 2032-12.
What conditions does trial NCT06170268 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT06170268?
The interventions under investigation include: Routine Care Documentation (OTHER).
Who is sponsoring clinical trial NCT06170268?
This trial is sponsored by Alzheimer's Disease and Related Disorders Association, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06170268 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06170268's enrollment target sits among peer trials
20,000 5th of 306 higher than 301 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
- NCT02735707 · 20,000 participants · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI